The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of docetaxel (DTX) and S-1 as neoadjuvant chemotherapy for potentially R0 advanced gastric cancer.
Masayuki Watanabe
Disclosure not yet available
Yasunori Emi
Disclosure not yet available
Yoshihiro Kakeji
Disclosure not yet available
Eiji Oki
Disclosure not yet available
Yoshihisa Sakaguchi
Disclosure not yet available
Kazuhiro Yoshida
Disclosure not yet available
Naoki Hirabayashi
Disclosure not yet available
Takeharu Yamanaka
Disclosure not yet available
Hideo Baba
Disclosure not yet available
Yoshihiko Maehara
Disclosure not yet available